These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 33931582)

  • 1. Anti-tumor activity of a novel proteasome inhibitor D395 against multiple myeloma and its lower cardiotoxicity compared with carfilzomib.
    Shen X; Wu C; Lei M; Yan Q; Zhang H; Zhang L; Wang X; Yang Y; Li J; Zhu Y; Chen L
    Cell Death Dis; 2021 Apr; 12(5):429. PubMed ID: 33931582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma.
    McBride A; Klaus JO; Stockerl-Goldstein K
    Am J Health Syst Pharm; 2015 Mar; 72(5):353-60. PubMed ID: 25694410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
    Kuhn DJ; Chen Q; Voorhees PM; Strader JS; Shenk KD; Sun CM; Demo SD; Bennett MK; van Leeuwen FW; Chanan-Khan AA; Orlowski RZ
    Blood; 2007 Nov; 110(9):3281-90. PubMed ID: 17591945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis.
    Shah C; Bishnoi R; Jain A; Bejjanki H; Xiong S; Wang Y; Zou F; Moreb JS
    Leuk Lymphoma; 2018 Nov; 59(11):2557-2569. PubMed ID: 29465266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
    Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
    Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
    Steele JM
    J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second Generation Proteasome Inhibitors in Multiple Myeloma.
    Gozzetti A; Papini G; Candi V; Brambilla CZ; Sirianni S; Bocchia M
    Anticancer Agents Med Chem; 2017; 17(7):920-926. PubMed ID: 27592543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiotoxicity of Carfilzomib in Two Japanese Patients with Relapsed Multiple Myeloma.
    Ikoma T; Saotome M; Sano M; Suwa K; Naruse Y; Ohtani H; Urushida T; Nagata Y; Ono T; Maekawa Y
    Intern Med; 2019 Jun; 58(11):1577-1581. PubMed ID: 30713316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
    Thompson JL
    Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of carfilzomib in the treatment of multiple myeloma.
    Khan RZ; Badros A
    Expert Rev Hematol; 2012 Aug; 5(4):361-72. PubMed ID: 22992230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
    Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
    Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
    Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
    Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay.
    Lee SJ; Levitsky K; Parlati F; Bennett MK; Arastu-Kapur S; Kellerman L; Woo TF; Wong AF; Papadopoulos KP; Niesvizky R; Badros AZ; Vij R; Jagannath S; Siegel D; Wang M; Ahmann GJ; Kirk CJ
    Br J Haematol; 2016 Jun; 173(6):884-95. PubMed ID: 27071340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation.
    Okabe S; Tanaka Y; Tauchi T; Ohyashiki K
    Ann Hematol; 2019 Mar; 98(3):723-733. PubMed ID: 30430191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carfilzomib in multiple myeloma.
    Andreu-Vieyra C; Berenson JR
    Expert Opin Biol Ther; 2014 Nov; 14(11):1685-99. PubMed ID: 25170966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.
    Stewart AK
    Future Oncol; 2015; 11(15):2121-36. PubMed ID: 26125319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
    Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
    Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular effect and efficacy of carfilzomib depends on cellular net concentration gradient.
    Schäfer J; Welti L; Seckinger A; Burhenne J; Theile D; Weiss J
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):71-79. PubMed ID: 28500557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carfilzomib: a novel agent for multiple myeloma.
    Redic K
    J Pharm Pharmacol; 2013 Aug; 65(8):1095-106. PubMed ID: 23837578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
    Kraus J; Kraus M; Liu N; Besse L; Bader J; Geurink PP; de Bruin G; Kisselev AF; Overkleeft H; Driessen C
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):383-96. PubMed ID: 26099967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.